JP2021066744A5 - ブプロピオンおよびデキストロメトルファンを含む組成物 - Google Patents
ブプロピオンおよびデキストロメトルファンを含む組成物 Download PDFInfo
- Publication number
- JP2021066744A5 JP2021066744A5 JP2021016211A JP2021016211A JP2021066744A5 JP 2021066744 A5 JP2021066744 A5 JP 2021066744A5 JP 2021016211 A JP2021016211 A JP 2021016211A JP 2021016211 A JP2021016211 A JP 2021016211A JP 2021066744 A5 JP2021066744 A5 JP 2021066744A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- bupropion
- dextromethorphan
- composition
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims 34
- SNPPWIUOZRMYNY-UHFFFAOYSA-N Bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 title claims 17
- MKXZASYAUGDDCJ-SZMVWBNQSA-N Dextromethorphan Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 title claims 16
- 229960001058 Bupropion Drugs 0.000 title claims 15
- 229960001985 Dextromethorphan Drugs 0.000 title claims 15
- 241000282412 Homo Species 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 4
- 229960004367 Bupropion Hydrochloride Drugs 0.000 claims 2
- 230000001430 anti-depressive Effects 0.000 claims 2
- 239000000935 antidepressant agent Substances 0.000 claims 2
- 239000012458 free base Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- ZEUITGRIYCTCEM-KRWDZBQOSA-N Duloxetine Chemical group C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 claims 1
- 206010057840 Major depression Diseases 0.000 claims 1
- 208000007979 Treatment-Resistant Depressive Disorder Diseases 0.000 claims 1
- 229960002866 duloxetine Drugs 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 239000007909 solid dosage form Substances 0.000 claims 1
- 230000002459 sustained Effects 0.000 claims 1
Images
Claims (26)
- ヒトの鬱病を治療する為の、ブプロピオンとデキストロメトルファンとを含む組成物であって、
前記組成物は、約１００ｍｇから約２００ｍｇのブプロピオンと、約４０ｍｇから約１００ｍｇのデキストロメトルファンとを含み、
前記組成物は、１日１回又は１日２回、少なくとも８日間連続で前記ヒトに投与され、
前記ヒトは、前記デキストロメトルファンの高代謝群である、
組成物。 - 前記鬱病が大鬱病である、請求項１に記載の組成物。
- 前記鬱病が治療抵抗性鬱病である、請求項１に記載の組成物。
- 前記ヒトが、少なくとも１つの抗うつ薬でうつ病の治療に失敗したことがある、請求項１に記載の組成物。
- 前記組成物を投与することは、同じ投与レジメンでブプロピオンを単独で投与するよりも、ヒトにおいてより大きな効果を提供する、請求項１から４のいずれか１項に記載の組成物。
- 前記組成物を投与することは、同じ投与レジメンでデキストロメトルファンを単独で投与するよりも、ヒトにおいてより大きな効果を提供する、請求項１から５のいずれか１項に記載の組成物。
- 約４０ｍｇから約６０ｍｇのデキストロメトルファンを含む、請求項１から６のいずれか１項に記載の組成物。
- 約４０ｍｇから約５０ｍｇのデキストロメトルファンを含む、請求項１から７のいずれか１項に記載の組成物。
- 約１００ｍｇから約１１０ｍｇのブプロピオンを含む、請求項１から８のいずれか１項に記載の組成物。
- 約１４０ｍｇから約１８０ｍｇのブプロピオンを含む、請求項１から８のいずれか１項に記載の組成物。
- 約１００ｍｇから約１５０ｍｇのブプロピオンを含む、請求項１から８のいずれか１項に記載の組成物。
- デキストロメトルファンが重水素変性デキストロメトルファンを含む、請求項１から１１のいずれか１項に記載の組成物。
- デキストロメトルファンの即時放出およびブプロピオンの持続放出を提供する、請求項１から１２のいずれか１項に記載の組成物。
- 少なくとも連続して１４日間、ヒトに経口投与される、請求項１から１３のいずれか１項に記載の組成物。
- 少なくとも連続して６０日間ヒトに経口投与される、請求項１から１３のいずれか１項に記載の組成物。
- 少なくとも連続して３０日間ヒトに経口投与される、請求項１から１０、１２および１３のいずれか１項に記載の組成物。
- １日１回で約１、２、３、４、５、６、または７日と、その後１日２回人間に投与される、請求項１から１６のいずれか１項に記載の組成物。
- 約４５ｍｇのデキストロメトルファンを含む、請求項１から１７のいずれか１項に記載の組成物。
- 約１０５ｍｇのブプロピオンを含む、請求項１から９のいずれか１項に記載の組成物。
- 約１５０ｍｇのブプロピオンを含む、請求項１から８のいずれか１項に記載の組成物。
- 抗うつ薬がデュロキセチンである、請求項４に記載の組成物。
- 約４０ｍｇから約７０ｍｇのデキストロメトルファンと、約１００ｍｇから約１４０ｍｇのブプロピオンと、を含む、請求項１から６および２１のいずれか１項に記載の組成物。
- 約１０５ｍｇの塩酸ブプロピオン、または、等モル当量のブプロピオンの遊離塩基または別形態の塩と、
遊離塩基形態のデキストロメトルファン約３０ｍｇから約４０ｍｇのモル当量の、塩形態のデキストロメトルファンと、を含む、
請求項１から６および２１のいずれか１項に記載の組成物。 - 前記組成物を１日２回投与することは、１０５ｍｇの塩酸ブプロピオンを１日２回単独で投与するよりも、ヒトにおいてより大きな効果を提供する、請求項２３に記載の組成物。
- １日分の用量１５０ｍｇから約２５０ｍｇのブプロピオン、および、１日分の用量約６０ｍｇから約１００ｍｇのデキストロメトルファンを含む前記組成物をヒトへ投与することが、同量のブプロピオンを単独で投与するよりも、ヒトにおいてより大きな効果を提供する、請求項１から６および２１に記載の組成物。
- デキストロメトルファンおよびブプロピオンが固体剤形中に存在する、請求項１から２５のいずれか１項に記載の組成物。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023014583A JP2023041862A (ja) | 2014-11-21 | 2023-02-02 | ニコチン中毒の治療が必要な人の治療のための医薬品の製造における、ブプロピオンまたはその薬学的に許容される塩と、デキストロメトルファンまたはその薬学的に許容される塩との組み合わせの使用 |
Applications Claiming Priority (16)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/550,618 | 2014-11-21 | ||
| US14/550,618 US9198905B2 (en) | 2013-11-05 | 2014-11-21 | Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects |
| US14/555,085 | 2014-11-26 | ||
| US14/554,947 US20150126542A1 (en) | 2013-11-05 | 2014-11-26 | Compositions and Methods for Increasing the Metabolic Lifetime of Dextromethorphan and Related Pharmacodynamic Effects |
| US14/554,947 | 2014-11-26 | ||
| US14/555,085 US9238032B2 (en) | 2013-11-05 | 2014-11-26 | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan |
| US14/554,988 US9205083B2 (en) | 2013-11-05 | 2014-11-26 | Compositions and methods comprising erythrohydroxybupropion and related compounds for improving the efficacy of dextromethorphan |
| US14/554,988 | 2014-11-26 | ||
| US14/602,177 | 2015-01-21 | ||
| US14/602,177 US9402843B2 (en) | 2013-11-05 | 2015-01-21 | Compositions and methods of using threohydroxybupropion for therapeutic purposes |
| US14/604,397 US9168234B2 (en) | 2013-11-05 | 2015-01-23 | Bupropion as a modulator of drug activity |
| US14/604,397 | 2015-01-23 | ||
| US14/617,624 | 2015-02-09 | ||
| US14/617,624 US9486450B2 (en) | 2013-11-05 | 2015-02-09 | Hydroxybupropion and related compounds as modulators of drug plasma levels |
| US14/628,062 | 2015-02-20 | ||
| US14/628,062 US9402844B2 (en) | 2013-11-05 | 2015-02-20 | Methods of modulating drug plasma levels using erythrohydroxybupropion |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019185676A Division JP6842129B2 (ja) | 2014-11-21 | 2019-10-09 | ブプロピオンまたは関連組成物およびデキストロメトルファンを含む組成物および方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023014583A Division JP2023041862A (ja) | 2014-11-21 | 2023-02-02 | ニコチン中毒の治療が必要な人の治療のための医薬品の製造における、ブプロピオンまたはその薬学的に許容される塩と、デキストロメトルファンまたはその薬学的に許容される塩との組み合わせの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021066744A JP2021066744A (ja) | 2021-04-30 |
| JP2021066744A5 true JP2021066744A5 (ja) | 2021-08-19 |
| JP7226839B2 JP7226839B2 (ja) | 2023-02-21 |
Family
ID=56014366
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017527254A Active JP6602863B2 (ja) | 2014-11-21 | 2015-05-01 | ブプロピオンまたは関連組成物およびデキストロメトルファンを含む医薬組成物 |
| JP2019185676A Active JP6842129B2 (ja) | 2014-11-21 | 2019-10-09 | ブプロピオンまたは関連組成物およびデキストロメトルファンを含む組成物および方法 |
| JP2021016211A Active JP7226839B2 (ja) | 2014-11-21 | 2021-02-04 | ブプロピオンおよびデキストロメトルファンを含む組成物 |
| JP2023014583A Pending JP2023041862A (ja) | 2014-11-21 | 2023-02-02 | ニコチン中毒の治療が必要な人の治療のための医薬品の製造における、ブプロピオンまたはその薬学的に許容される塩と、デキストロメトルファンまたはその薬学的に許容される塩との組み合わせの使用 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017527254A Active JP6602863B2 (ja) | 2014-11-21 | 2015-05-01 | ブプロピオンまたは関連組成物およびデキストロメトルファンを含む医薬組成物 |
| JP2019185676A Active JP6842129B2 (ja) | 2014-11-21 | 2019-10-09 | ブプロピオンまたは関連組成物およびデキストロメトルファンを含む組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023014583A Pending JP2023041862A (ja) | 2014-11-21 | 2023-02-02 | ニコチン中毒の治療が必要な人の治療のための医薬品の製造における、ブプロピオンまたはその薬学的に許容される塩と、デキストロメトルファンまたはその薬学的に許容される塩との組み合わせの使用 |
Country Status (22)
| Country | Link |
|---|---|
| EP (2) | EP3763372A1 (ja) |
| JP (4) | JP6602863B2 (ja) |
| KR (6) | KR102376868B1 (ja) |
| CN (2) | CN107205998A (ja) |
| AU (3) | AU2015350559C1 (ja) |
| CA (3) | CA3082645C (ja) |
| CY (1) | CY1123571T1 (ja) |
| DK (1) | DK3220909T3 (ja) |
| ES (1) | ES2835304T3 (ja) |
| HK (1) | HK1243323A1 (ja) |
| HR (1) | HRP20201855T1 (ja) |
| HU (1) | HUE052609T2 (ja) |
| IL (3) | IL297349A (ja) |
| LT (1) | LT3220909T (ja) |
| MX (3) | MX2021001442A (ja) |
| MY (1) | MY189466A (ja) |
| PL (1) | PL3220909T3 (ja) |
| PT (1) | PT3220909T (ja) |
| RS (1) | RS61113B1 (ja) |
| SG (2) | SG11201704066VA (ja) |
| SI (1) | SI3220909T1 (ja) |
| WO (1) | WO2016081027A1 (ja) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220233470A1 (en) | 2013-11-05 | 2022-07-28 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11285118B2 (en) | 2013-11-05 | 2022-03-29 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11229640B2 (en) | 2013-11-05 | 2022-01-25 | Antecip Bioventures Ii Llc | Combination of dextromethorphan and bupropion for treating depression |
| US11571417B2 (en) | 2013-11-05 | 2023-02-07 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11382874B2 (en) | 2013-11-05 | 2022-07-12 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11419867B2 (en) | 2013-11-05 | 2022-08-23 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11617747B2 (en) | 2013-11-05 | 2023-04-04 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11197839B2 (en) | 2013-11-05 | 2021-12-14 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11191739B2 (en) | 2013-11-05 | 2021-12-07 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11298351B2 (en) | 2013-11-05 | 2022-04-12 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11478468B2 (en) | 2013-11-05 | 2022-10-25 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11426370B2 (en) | 2013-11-05 | 2022-08-30 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11534414B2 (en) | 2013-11-05 | 2022-12-27 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11426401B2 (en) | 2013-11-05 | 2022-08-30 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11439636B1 (en) | 2013-11-05 | 2022-09-13 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11364233B2 (en) | 2013-11-05 | 2022-06-21 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11576877B2 (en) | 2013-11-05 | 2023-02-14 | Antecip Bioventures Ii Llc | Bupropion as modulator of drug activity |
| US11517543B2 (en) | 2013-11-05 | 2022-12-06 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11510918B2 (en) | 2013-11-05 | 2022-11-29 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11291665B2 (en) | 2013-11-05 | 2022-04-05 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11357744B2 (en) | 2013-11-05 | 2022-06-14 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11524007B2 (en) | 2013-11-05 | 2022-12-13 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11590124B2 (en) | 2013-11-05 | 2023-02-28 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11596627B2 (en) | 2013-11-05 | 2023-03-07 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11344544B2 (en) | 2013-11-05 | 2022-05-31 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11969421B2 (en) | 2013-11-05 | 2024-04-30 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11433067B2 (en) | 2013-11-05 | 2022-09-06 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11298352B2 (en) | 2013-11-05 | 2022-04-12 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11617728B2 (en) | 2013-11-05 | 2023-04-04 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11541048B2 (en) | 2013-11-05 | 2023-01-03 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11541021B2 (en) | 2013-11-05 | 2023-01-03 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11576909B2 (en) | 2013-11-05 | 2023-02-14 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11207281B2 (en) | 2013-11-05 | 2021-12-28 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11497721B2 (en) | 2013-11-05 | 2022-11-15 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11571399B2 (en) | 2013-11-05 | 2023-02-07 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| KR102376868B1 (ko) * | 2014-11-21 | 2022-03-18 | 안테씨프 바이오벤쳐스 투 엘엘씨 | 에리트로히드록시부프로피온을 이용한 약물의 혈장 농도의 조절 방법 |
| AU2020207261B2 (en) * | 2019-01-07 | 2023-04-13 | Antecip Bioventures Ii Llc | Combination of dextromethorphan and bupropion for treating depression |
| CN117100750A (zh) * | 2020-07-20 | 2023-11-24 | 深圳信立泰药业股份有限公司 | 一种药物组合物及其应用 |
| US11717518B1 (en) | 2022-06-30 | 2023-08-08 | Antecip Bioventures Ii Llc | Bupropion dosage forms with reduced food and alcohol dosing effects |
| US11730706B1 (en) | 2022-07-07 | 2023-08-22 | Antecip Bioventures Ii Llc | Treatment of depression in certain patient populations |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5350756A (en) * | 1991-06-17 | 1994-09-27 | Smith Richard A | Use of a cytochrome oxidase inhibitor to increase the cough-suppressing activity of dextromorphan |
| JP2009525343A (ja) * | 2006-02-03 | 2009-07-09 | アバニール・ファーマシューティカルズ | 鬱病、不安および神経変性疾患を治療するためのデキストロメトルファンおよびキニジンを含む薬剤組成物 |
| WO2009006194A1 (en) | 2007-06-28 | 2009-01-08 | Avanir Pharmaceuticals | Pharmaceutical compositions for the treatment of involuntary emotional expression disorder |
| WO2012118562A1 (en) | 2011-03-02 | 2012-09-07 | Rhine Pharmaceuticals, Llc | Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations |
| US20130274282A1 (en) * | 2012-04-16 | 2013-10-17 | Herriot Tabuteau | Compositions and methods comprising celecoxib or related compounds and dextromethorphan |
| CN110251517A (zh) * | 2013-11-05 | 2019-09-20 | 安泰赛普生物风投二代有限责任公司 | 包含安非他酮或相关化合物和右美沙芬的组合物和方法 |
| US9198905B2 (en) | 2013-11-05 | 2015-12-01 | Antecip Bioventures Ii Llc | Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects |
| US9402843B2 (en) | 2013-11-05 | 2016-08-02 | Antecip Bioventures Ii Llc | Compositions and methods of using threohydroxybupropion for therapeutic purposes |
| KR102376868B1 (ko) * | 2014-11-21 | 2022-03-18 | 안테씨프 바이오벤쳐스 투 엘엘씨 | 에리트로히드록시부프로피온을 이용한 약물의 혈장 농도의 조절 방법 |
-
2015
- 2015-05-01 KR KR1020217014289A patent/KR102376868B1/ko active IP Right Grant
- 2015-05-01 EP EP20193845.3A patent/EP3763372A1/en active Pending
- 2015-05-01 MY MYPI2017701828A patent/MY189466A/en unknown
- 2015-05-01 SI SI201531421T patent/SI3220909T1/sl unknown
- 2015-05-01 JP JP2017527254A patent/JP6602863B2/ja active Active
- 2015-05-01 SG SG11201704066VA patent/SG11201704066VA/en unknown
- 2015-05-01 KR KR1020237012943A patent/KR102640586B1/ko active IP Right Grant
- 2015-05-01 CN CN201580074124.7A patent/CN107205998A/zh active Pending
- 2015-05-01 KR KR1020247005737A patent/KR20240027872A/ko not_active Application Discontinuation
- 2015-05-01 DK DK15861189.7T patent/DK3220909T3/da active
- 2015-05-01 CA CA3082645A patent/CA3082645C/en active Active
- 2015-05-01 KR KR1020177017050A patent/KR101931896B1/ko active IP Right Grant
- 2015-05-01 MX MX2021001442A patent/MX2021001442A/es unknown
- 2015-05-01 IL IL297349A patent/IL297349A/en unknown
- 2015-05-01 CA CA3232022A patent/CA3232022A1/en active Pending
- 2015-05-01 CN CN202010202397.8A patent/CN111297860A/zh active Pending
- 2015-05-01 AU AU2015350559A patent/AU2015350559C1/en active Active
- 2015-05-01 EP EP15861189.7A patent/EP3220909B1/en active Active
- 2015-05-01 PL PL15861189T patent/PL3220909T3/pl unknown
- 2015-05-01 RS RS20201405A patent/RS61113B1/sr unknown
- 2015-05-01 KR KR1020227008513A patent/KR102524253B1/ko active IP Right Grant
- 2015-05-01 WO PCT/US2015/028901 patent/WO2016081027A1/en active Application Filing
- 2015-05-01 MX MX2017006653A patent/MX2017006653A/es unknown
- 2015-05-01 PT PT158611897T patent/PT3220909T/pt unknown
- 2015-05-01 HU HUE15861189A patent/HUE052609T2/hu unknown
- 2015-05-01 LT LTEP15861189.7T patent/LT3220909T/lt unknown
- 2015-05-01 KR KR1020187036244A patent/KR102253986B1/ko active IP Right Grant
- 2015-05-01 IL IL280905A patent/IL280905B2/en unknown
- 2015-05-01 CA CA2968371A patent/CA2968371C/en active Active
- 2015-05-01 ES ES15861189T patent/ES2835304T3/es active Active
- 2015-05-02 SG SG10201911873XA patent/SG10201911873XA/en unknown
-
2017
- 2017-05-19 MX MX2023000320A patent/MX2023000320A/es unknown
- 2017-05-21 IL IL252417A patent/IL252417B/en active IP Right Grant
-
2018
- 2018-02-26 HK HK18102743.6A patent/HK1243323A1/zh unknown
-
2019
- 2019-03-06 AU AU2019201548A patent/AU2019201548C1/en active Active
- 2019-10-09 JP JP2019185676A patent/JP6842129B2/ja active Active
-
2020
- 2020-11-20 HR HRP20201855TT patent/HRP20201855T1/hr unknown
- 2020-11-24 CY CY20201101110T patent/CY1123571T1/el unknown
-
2021
- 2021-02-04 JP JP2021016211A patent/JP7226839B2/ja active Active
- 2021-02-15 AU AU2021200981A patent/AU2021200981A1/en active Pending
-
2023
- 2023-02-02 JP JP2023014583A patent/JP2023041862A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021066744A5 (ja) | ブプロピオンおよびデキストロメトルファンを含む組成物 | |
| JP2023041862A5 (ja) | ||
| JP2016106150A5 (ja) | ||
| HRP20210487T1 (hr) | Farmaceutski sastavi koji sadrže lokalni anestetik kao što je bupivakain za lokalnu primjenu u usta ili grlo | |
| JP2009525343A5 (ja) | ||
| BRPI0518266A2 (pt) | medicamento oral de libertaÇço modificada de pelo menos um princÍpio ativo sob a forma multimicrocapsular | |
| JP2015038135A5 (ja) | ||
| HRP20220902T3 (hr) | Pripravci i njihova upotreba u liječenju multiple skleroze | |
| AR048431A1 (es) | Formulaciones galenicas de compuestos organicos | |
| HRP20120147T1 (hr) | Titracija tapentadola | |
| RU2010147287A (ru) | Комбинированная композиция | |
| RU2008119454A (ru) | Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом | |
| HRP20230272T1 (hr) | Postupci za liječenje cistične fibroze | |
| CO6260019A2 (es) | Metodos para el tratamiento de desordenes gastrointestinales independientes de la ingesta de alimento | |
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| JP2013231087A5 (ja) | ||
| RS54050B1 (en) | FORMULATIONS AND METHODS FOR THE TREATMENT OF AMYLOIDOSIS | |
| RU2011137131A (ru) | Производные 1-аминоалкилциклогексана для лечения тиннитуса, связанного с потерей слуха или незначительной потерей слуха | |
| SK14612003A3 (sk) | Použitie enantiomérne čistého escitalopramu a farmaceutický prostriedok s obsahom escitalopramu | |
| JP2006516272A5 (ja) | ||
| JP2018138596A5 (ja) | ||
| JP2018521007A5 (ja) | ||
| ECSP078014A (es) | Regimen de dosificacion para prasugrel | |
| HRP20230300T1 (hr) | Kombinacije imetelstata i venetoklaksa za liječenje akutne mijeloidne leukemije | |
| JP2011500589A5 (ja) |